Celularity (CELU) Net Income towards Common Stockholders Growth (1y) (2020 - 2025)
Celularity (CELU) Net Income towards Common Stockholders Growth (1y) (2020 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -6.81% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 92.37% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.21% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 151.28% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 327.74% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -147.59% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 95.87% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -12.04% |
| 10 | Celularity | 20.99 Mn | 14.82 Mn | -3.27 Mn | -83.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -83.49% |
| Sep 30, 2025 | -43.31% |
| Jun 30, 2025 | -278.04% |
| Mar 31, 2025 | 9.99% |
| Dec 31, 2024 | -239.22% |
| Sep 30, 2024 | 82.85% |
| Jun 30, 2024 | 86.47% |
| Mar 31, 2024 | 65.61% |
| Dec 31, 2023 | -60.93% |
| Sep 30, 2023 | -2,056.16% |
| Jun 30, 2023 | -200.26% |
| Mar 31, 2023 | -1.83% |
| Dec 31, 2022 | 704.80% |
| Sep 30, 2022 | -90.39% |
| Jun 30, 2022 | 174.13% |
| Mar 31, 2022 | 22.86% |
| Dec 31, 2021 | -400.62% |
| Sep 30, 2021 | 207.80% |
| Jun 30, 2021 | -432.80% |
| Mar 31, 2021 | -1,379.68% |